Issues with our digital services

We're investigating why they're not working as they should. Please bear with us.

DNA viruses in adult allogeneic HSCT recipients. Version 1.

  • Research type

    Research Study

  • Full title

    Longitudinal analysis of DNA viruses and host immunophenotyping in adult allogeneic haematopoetic stem cell transplant (HSCT) recipients

  • IRAS ID

    264626

  • Contact name

    Julia Colston

  • Contact email

    julia.colston@ndm.ox.ac.uk

  • Sponsor organisation

    University of Oxford / Clinical Trials and Research Governance

  • Duration of Study in the UK

    2 years, 11 months, 31 days

  • Research summary

    This observational study looks to identify epidemiological trends within allogeneic transplant recipients of DNA viruses, particularly Cytomegalovirus (CMV) and Epstein-Barr virus (EBV). These viruses cause significant morbidity and mortality in this cohort and better understanding of viral evolution and antiviral resistance, in the context of the individual host, is required to improve clinical management.

    This study looks to use next generation sequencing techniques (NGS) to track the viral evolution longitudinally within the host and match this information to the participant data (clinical progress and therapies). Where applicable, NGS will also be used to evaluate the host immune response, specifically to look at T cell receptor responses and the adaptive immunity within the host.

    The study focusses on all adult allogeneic transplant recipients within the Oxford cohort who are 18 years or older and able to consent to participation at the time of enrolment.

    The study is based upon Oxford Haematology patients only, within the Haematology Department at The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.

    The study will involve a 3-year acquisition period, whereby all patients being put forward to an allogeneic stem-cell transplant will be consented into the study. Where participants reactivate a DNA virus (as identified from routine clinical screening) these clinical samples (the residual sample, which is usually disposed of) will be used for longitudinal analysis of the virus in the host and the host responses. No additional visits or sampling outside of the routine NHS clinical care are required for the purposes of this study.

  • REC name

    London - West London & GTAC Research Ethics Committee

  • REC reference

    19/LO/0977

  • Date of REC Opinion

    15 Jul 2019

  • REC opinion

    Further Information Favourable Opinion